Kisspeptin and Letrozole Interaction: Synergistic | Peptide Database

YK-11's dual mechanism of AR agonism and myostatin inhibition theoretically positions it as a potent anabolic compound for increasing lean muscle mass. Cell culture data supports increased anabolic signaling and follistatin expression. However, there is no in vivo or clinical evidence confirming these effects in animals or humans. All efficacy reports are anecdotal. Users anecdotally report significant strength gains during YK-11 cycles, consistent with the compound's theoretical mechanism of action. The combination of AR-mediated protein synthesis and myostatin inhibition could theoretically support enhanced force production. No controlled studies exist to verify these claims. The most distinctive proposed benefit of YK-11 is its ability to upregulate follistatin and thereby inhibit myostatin-mediated limitations on muscle growth. In cell culture, YK-11 induced greater follistatin expression than DHT. If this translates to in vivo activity, it could allow muscle growth beyond normal physiological limits. This remains entirely unproven outside of cell-based assays. Follistatin has been shown in other research contexts to positively influence bone mineral density and bone formation. If YK-11's follistatin-inducing effects translate in vivo, there could be secondary benefits for bone density. This is entirely speculative and unsupported by any direct YK-11 bone data.

Join others researching Meldonium — share findings, ask questions, and learn from real experiences Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis. Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.